Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies

Experimental Dermatology

Volumn 19, Issue 10, 2010, Pages 904-911

  Clos, Audra L ^a   Lasagna Reeves, Cristian A ^a   Wagner, Richard ^a   Kelly, Brent ^a   Jackson, George R ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cutaneous amyloidosis; Fibrils and conformational antibodies; Oligomers

Indexed keywords

AMYLOID; ANTIBODY;

AMYLOIDOSIS; ANIMAL; ARTICLE; BIOPSY; C57BL MOUSE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MOUSE; PATHOLOGY; SKIN DISEASE;

AMYLOID; AMYLOIDOSIS; ANIMALS; ANTIBODIES; BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, INBRED C57BL; SKIN DISEASES;

EID: 79952110086     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01121.x     Document Type: Article

References (50)

1. Stefani M, Dobson C M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003: 81: 678-699.
2. Chiti F, Dobson C M. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006: 75: 333-366.
3. Meersman F, Dobson C M, Heremans K. Protein unfolding, amyloid fibril formation and configurational energy landscapes under high pressure conditions. Chem Soc Rev 2006: 35: 908-917.
4. Herczenik E, Gebbink M F. Molecular and cellular aspects of protein misfolding and disease. FASEB J 2008: 22: 2115-2133.
5. Pastor M T, Kummerer N, Schubert V et al. Amyloid toxicity is independent of polypeptide sequence, length and chirality. J Mol Biol 2008: 375: 695-707.
6. Bucciantini M, Calloni G, Chiti F et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 2004: 279: 31374-31382.
7. Westermark P, Lundmark K, Westermark G T. Fibrils from designed non-amyloid-related synthetic peptides induce AA-amyloidosis during inflammation in an animal model. PLoS ONE 2009: 4: e6041.
8. Glabe C G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006: 27: 570-575.
9. Glabe C G, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006: 66: S74-S78.
10. Tillement J P, Lecanu L, Papadopoulos V. Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options. Pharmacology 2009: 85: 1-17.
11. Bhat A, Selmi C, Naguwa S M, Cheema G S, Gershwin M E. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 2009: 38: 97-106.
12. Schwendiman M N, Beachkofsky T M, Wisco O J, Owens N M, Hodson D S. Primary cutaneous nodular amyloidosis: case report and review of the literature. Cutis 2009: 84: 87-92.
13. Feito-Rodriguez M, Garcia-Macarron J, Pagan-Munoz B et al. [Disseminated nodular primary localized cutaneous amyloidosis]. Actas Dermosifiliogr 2008: 99: 648-652.
14. Katsikas G A, Maragou M, Rontogianni D, Gouma P, Koutsouvelis I, Kappou-Rigatou I. Secondary cutaneous nodular AA amyloidosis in a patient with primary Sjogren syndrome and celiac disease. J Clin Rheumatol 2008: 14: 27-29.
15. Touart D M, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol 1998: 39: 527-544.
16. Lee E B, Leng L Z, Zhang B et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006: 281: 4292-4299.
17. Solomon B, Frenkel D. Vaccination for the prevention and treatment of Alzheimer's disease. Drugs Today (Barc) 2000: 36: 655-663.
18. Sigurdsson E M. Immunotherapy for conformational diseases. Curr Pharm Des 2006: 12: 2569-2585.
19. Hrncic R, Wall J, Wolfenbarger D A et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000: 157: 1239-1246.
20. Kayed R, Head E, Sarsoza F et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007: 2: 18.
21. Kayed R, Head E, Thompson J L et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003: 300: 486-489.
22. Kitazawa M, Vasilevko V, Cribbs D H, LaFerla F M. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci 2009: 29: 6132-6141.
23. Chauhan N B. Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 2007: 85: 451-463.
24. Lundmark K, Westermark G T, Nystrom S, Murphy C L, Solomon A, Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 2002: 99: 6979-6984.
25. Lundmark K, Westermark G T, Olsen A, Westermark P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci U S A 2005: 102: 6098-6102.
26. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 1996: 93: 452-455.
27. Lin C Y, Gurlo T, Kayed R et al. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 2007: 56: 1324-1332.
28. Ganowiak K, Hultman P, Engstrom U, Gustavsson A, Westermark P. Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 1994: 199: 306-312.
29. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin E C. The characterization of soluble amyloid prepared in water. J Clin Invest 1968: 47: 924-933.
30. Glabe C G. Structural classification of toxic amyloid oligomers. J Biol Chem 2008: 283: 29639-29643.
31. Brody D L, Holtzman D M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008: 31: 175-193.
32. Mamikonyan G, Necula M, Mkrtichyan M et al. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 2007: 282: 22376-22386.
33. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997: 94: 4109-4112.
34. Masliah E, Hansen L, Adame A et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005: 64: 129-131.
35. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999: 400: 173-177.
36. Urushitani M, Ezzi S A, Julien J P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007: 104: 2495-2500.
37. Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005: 46: 857-868.
38. Orgogozo J M, Gilman S, Dartigues J F et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003: 61: 46-54.
39. Nicoll J A, Wilkinson D, Holmes C, Steart P, Markham H, Weller R O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003: 9: 448-452.
40. Ferrer I, Boada Rovira M, Sanchez Guerra M L, Rey M J, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004: 14: 11-20.
41. Wilcock D M, Rojiani A, Rosenthal A et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004: 1: 24.
42. Racke M M, Boone L I, Hepburn D L et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005: 25: 629-636.
43. Pfeifer M, Boncristiano S, Bondolfi L et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002: 298: 1379.
44. Nikolic W V, Bai Y, Obregon D et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A 2007: 104: 2507-2512.
45. Bacskai B J, Kajdasz S T, McLellan M E et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002: 22: 7873-7878.
46. Amit A G, Mariuzza R A, Phillips S E, Poljak R J. Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science 1986: 233: 747-753.
47. Davies D R, Cohen G H. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 1996: 93: 7-12.
48. Frauenfelder H, Petsko G A, Tsernoglou D. Temperature-dependent X-ray diffraction as a probe of protein structural dynamics. Nature 1979: 280: 558-563.
49. Karplus M, Petsko G A. Molecular dynamics simulations in biology. Nature 1990: 347: 631-639.
50. Deane J A, Hickey M J. Molecular mechanisms of leukocyte trafficking in T-cell-mediated skin inflammation: insights from intravital imaging. Expert Rev Mol Med 2009: 11: e25.